Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
We evaluated neuropathological findings in two studies of AAV2-GDNF efficacy and safety in naive aged (>20 years) or MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-lesioned rhesus macaques. In the first study, a total of 17 animals received one of two doses of AAV2-GDNF into either putamen or substantia nigra (SN). To control for surgical variables, all animals received identical putaminal and nigral infusions in which phosphate-buffered saline was substituted for vector as appropriate. All 17 aged monkeys were studied for 6 months before necropsy. In a separate study, 11 MPTP-lesioned rhesus macaques with extensive lesions in the right SN and mild lesions in the left SN received bilateral infusions of AAV2-GDNF (9.9 x 10(11) vector genomes) or PBS into the putamen and were then studied for up to 14 months. In the current analysis, we addressed safety issues regarding AAV2-GDNF administration. An extensive series of assessments of in-life behavioral and clinical parameters was conducted. No overt histopathology or immune responses were detected in any experimental monkey. However, the delivery of AAV2-GDNF to the SN of aged monkeys caused a marked and significant loss of body weight (-19.4%). No weight loss was observed in the MPTP-lesioned monkeys despite bilateral axonal transport of glial cell line-derived neurotrophic factor (GDNF) to the SN from the putamen. These findings indicate that putaminal administration of AAV2-GDNF by convection-enhanced delivery shows therapeutic promise without any apparent side effects. Importantly, nigral administration of AAV2-GDNF caused significant weight loss that raises substantial concern for clinical application of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079 · cited 1×
“…of recombinant GDNF protein or virus-mediated GDNF gene elevation in the substantia nigra or striatum re-sults in the protection of dopaminergic neurons in neurotox-icant models (Kearns and Gash, 1995; Tomac et al. , 1995; Kordower et al. , 2000; Maswood et al. , 2002; Grondin et al. , 2003).”
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 1×
“This suggests that anterograde, rather than retrograde, transport is the predominant means by which GDNF is disseminated to distal locations, although clearly retrograde transport of AAV2 also occurs under some conditions (Kaspar et al. , 2003; Kells et al. , 2009).”
Peden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222 · cited 1×
“Preexisting humoral immunity to AAV2 vector or a humoral response resulting from AAV2-GDNF administration may reduce transgene expression (Sanftner et al. , 2004) or cause inflammation (Peden et al. , 2004, 2009).”
Striatal Delivery of rAAV-hAADC to Rats with Preexisting Immunity to AAV
Sanftner, L. M., Suzuki, B. M., Doroudchi, M. M., Feng, L., McClelland, A., Forsayeth, J. R., & Cunningham, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.005 · Cited by 89
Self-citationPeden, C. S., Manfredsson, F. P., Reimsnider, S. K., Poirier, A. E., Burger, C., Muzyczka, N., & Mandel, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.284 · Cited by 44 · cited 3×
“…observation is in accordance with previous reports of weight loss in rats with nigral or hypothalamic delivery of AAV2-GDNF (Tumer et al. , 2006; Manfredsson et al. , 2009) and with reports describing similar, although transient, weight loss after intracerebroventricular (ICV) infusion of…”
Research works printed but not linked: 28
- 10.1006/exnr.2000.7408 · DOI · Paper page
- 10.1016/S0006-8993(01)03253-X · DOI
- 10.1038/mt.2008.111 · DOI · Paper page
- 10.1002/glia.1107 · DOI · Paper page
- 10.1089/hum.2008.201 · DOI · Paper page
- 10.1016/S0006-8993(98)00710-0 · DOI
- 10.1007/s12035-008-8043-y · DOI
- 10.1523/JNEUROSCI.20-09-03182.2000 · DOI · Paper page
- Grondin R., 2003, J. Neurosci., 23, 1974, 10.1523/JNEUROSCI.23-05-01974.2003 · DOI · Paper page
- 10.1177/01926230701481899 · DOI · Paper page
- 10.1089/hum.2008.137 · DOI · Paper page
- 10.1016/0304-3940(81)90400-6 · doi:10.1016/0304-3940(81)90400-6
- 10.1016/0006-8993(94)01366-P · DOI · Paper page
- 10.1073/pnas.0810682106 · DOI · Paper page
- 10.1126/science.290.5492.767 · DOI · Paper page
- 10.1002/ana.20737 · DOI · Paper page
- 10.1038/mt.2009.45 · DOI · Paper page
- 10.1016/S0006-8993(02)03694-6 · DOI
- 10.1111/j.1460-9568.1996.tb01293.x · DOI
- 10.1016/S0197-4580(02)00022-2 · DOI
- 10.1002/cne.10898 · DOI · Paper page
- 10.1212/WNL.60.1.69 · DOI · Paper page
- 10.1002/mds.21013 · DOI · Paper page
- 10.1038/nn.2136 · DOI · Paper page
- 10.1016/S0074-7742(07)82005-8 · DOI · Paper page
- 10.1038/sj.gt.3302377 · DOI
- 10.1016/j.neurobiolaging.2005.03.018 · DOI
- Zhang Z., 1997, J. Pharmacol. Exp. Ther., 282, 1396, 10.1016/S0022-3565(24)36963-0 · DOI
Cited by
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
“the substantia nigra-treated group (Su et al., 2009).”
Tet-On Systems For Doxycycline-inducible Gene Expression
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160524144041 · Cited by 434
“Several inducible or repressible genetic systems to regulate intracerebral delivery of GDNF, which is envisaged for the treatment of Parkinson’s disease [27] (https://clinical trials.”
BackgroundTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Gene Therapy for Neurodegenerative Diseases
Sudhakar, V., & Richardson, R. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00694-0 · Cited by 212
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Hadaczek, P., Eberling, J. L., Pivirotto, P., Bringas, J., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.106 · Cited by 158
Self-citationSu, X., Kells, A. P., Salegio, E. A., Richardson, R. M., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.114 · Cited by 82
Self-citationDestination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55
“Several studies are testing safe, effective, and non-invasive therapeutic strategies for NDDs by attempting delivery of drugs (Geldenhuys et al. 2011), proteins (Chaturvedi et al. 2014), and genes (Su et al. 2009) to cure disease or to slow its development .”
San Sebastian, W., Richardson, R. M., Kells, A. P., Lamarre, C., Bringas, J., Pivirotto, P., Salegio, E. A., DeArmond, S. J., Forsayeth, J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.162 · Cited by 48
“3b and c), consistent with previous reports demonstrating slight inflammation after CED from a stepped cannula (Su et al., 2009).”
ResultSelf-citationChtarto, A., Humbert-Claude, M., Bockstael, O., Das, A. T., Boutry, S., Breger, L. S., Klaver, B., Melas, C., Barroso-Chinea, P., Gonzalez-Hernandez, T., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.27 · Cited by 43
T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery
Richardson, R. M., Gimenez, F., Salegio, E. A., Su, X., Bringas, J., Berger, M. S., & Bankiewicz, K. S. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318217217e · Cited by 38
“Each animal had undergone a previous neurosurgical procedure to implant cranial access ports using previously established techniques.(6) During MRI, the animal was sedated with ketamine (Ketaset, 7 mg/kg, intramuscular) and xylazine (Rompun, 3 mg/kg, intramuscular), intubated, and placed on inhaled isoflurane (1%-3%).”
MethodSelf-citationFajardo-Serrano, A., Rico, A. J., Roda, E., Honrubia, A., Arrieta, S., Ariznabarreta, G., Chocarro, J., Lorenzo-Ramos, E., Pejenaute, A., Vázquez, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126389 · Cited by 32
de Silva, S., & J. Bowers, W. (2011) · Current Gene Therapy · doi:10.2174/156652311797415845 · Cited by 20
“the glial-derived neurotrophic factor (GDNF) and Neurturin to the putamen region of the brain in order to protect and restore dopaminergic neuron function during the progression of PD [10, 11].”
Background
Metadata
- Authors
- Su, X., Kells, A. P., Huang, E. J., Lee, H. S., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Penticuff, J., Eberling, J., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2009-12
- Volume
- 20
- Issue
- 12
- Pages
- 1627-1640
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2081188627
- Cited by
- 112
- References
- 5
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.